BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

   -- CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with 
      data readout expected mid-2025; Dose expansion data readout anticipated 
      1H 2026 
 
   -- Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with 
      exceptional overall survival (OS) with 66% and 58% of patients with mKRAS 
      NSCLC alive at a landmark one-year and two-years, respectively, which 
      exceeds the reported standard of care 
 
   -- Ozuriftamab vedotin (CAB-ROR2-ADC) demonstrated compelling anti-tumor 
      activity in treatment-refractory, metastatic HPV-positive squamous cell 
      carcinoma of the head and neck (SCCHN); a population which is poorly 
      served by EGFR inhibitors 
 
   -- Cash balance of $49mm at year-end 2024 with recent cost-reduction 
      measures expected to further extend runway beyond key clinical readouts 
      in 1H 2026 
 
   -- Management to host conference call and webcast today at 4:30 PM Eastern 
      Time 

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided highlights on its clinical programs.

"We are encouraged by the differentiated clinical outcomes observed in our evolving CAB platform program datasets," said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc., "In our Phase 1 dose-escalation study evaluating dual conditionally-binding EpCAM and CD3 in the exciting T cell engager space, we continue to observe encouraging results, with multiple patients achieving tumor reduction and tolerating the therapy over many months without progression. Dose escalation continues and we remain on track for this clinical data readout in mid-2025. We are also observing meaningful improvement in our clinical datasets across our CAB platform programs in terms of tumor reduction and overall survival in key unmet need patient populations. As a result, we continue to advance multiple discussions with potential collaborators on our Phase 2 assets, as well as initiate new ones. Finally, we restructured the organization to further reduce costs, extend runway and prioritize new patient recruitment to programs that we believe can provide transformative results for our patients and shareholders alike."

Key Developments, Operational Updates and Upcoming Milestones

Programs Advancing Internally

   -- Phase 1/2 dose-escalation for conditionally-binding BA3182 (CAB-EpCAM x 
      CAB-CD3 TCE) (NCT05808634) in heavily pretreated patients with 
      unresectable or metastatic adenocarcinoma 
 
          -- Phase 1 dose escalation ongoing and on track with data readout 
             mid-2025, given encouraging continued ongoing dose escalation with 
             increasing antitumor activity. 
 
                 -- Observed multiple patients with tumor reduction, including 
                    a colorectal cancer patient with stable disease for greater 
                    than one year. 
 
                 -- Maximally tolerated dose has not yet been reached. 
 
          -- Currently dosing QW cohorts with priming dose and a 100 microgram 
             ongoing treatment dose. Two of three patients have cleared this 
             dose level and we anticipate dosing the 300 microgram cohort once 
             the final patient clears the dose-limiting toxicity $(DLT.AU)$ period 
             on April 8th. 
 
          -- In parallel we are enrolling a priming and intermediate step dose, 
             followed by the 100 microgram ongoing treatment dose. 
 
          -- Cohort expansion data readout anticipated 1H 2026. 
 
   -- Phase 2 trial of mecbotamab vedotin (Mec-V), CAB-AXL-ADC (NCT04681131) in 
      NSCLC (median of 3 prior lines of treatment) 
 
          -- Promising anti-tumor activity among 17 patients whose tumors 
             express mKRAS mutations with multiple confirmed responses at the 
             1.8 mg/kg Q2W dosing regimen 
 
                 -- Data presented at the European Lung Cancer Congress on 
                    March 27, 2025 here 
 
                 -- Q2W dosing regimen associated with exceptional OS and 
                    encouraging clinical benefit / risk profile 
 
                        -- 66% of patients alive at a landmark of one year; 58% 
                           of patients alive at landmark of two years 
 
                        -- Median OS not reached at 35 months from first dose, 
                           ongoing 
 
                 -- Responses and preliminary clinical benefit demonstrated 
                    across nine different mKRAS variants 
 
                        -- PR observed in a patient who had experienced prior 
                           failure of sotorasib 
 
                        -- Patient treated with mec-V + anti-PD-1 antibody 
                           remains in CR for >2 years 
   -- Continue to observe a high correlation of AXL and mKRAS expression. 
 
   -- Generally well-tolerated with and without nivolumab; no new safety 
      signals identified with only 7% discontinuation due to related AEs. 
 
   -- Potential for a pan mKRAS strategy in NSCLC; currently positioning asset 
      for a future pivotal trial with Phase 2 clinical data readout in 1H26 

Phase 2 Programs Planned for Advancement Through Corporate Partnerships

   -- Phase 2 Trial of ozuriftamab vedotin (Oz-V), CAB-ROR2-ADC (NCT05271604) 
      in treatment-refractory SCCHN (median of 3 prior lines of treatment) 
 
          -- Oz-V monotherapy continues to deliver responses among patients 
             with 2L+ SCCHN at the 1.8 mg/kg Q2W dosing regimen; ORR, DOR, PFS, 
             and OS data capture ongoing 
 
          -- Updated data presented at the Mayo Multidisciplinary Head and Neck 
             Cancer Symposium on March 27, 2025 here 
 
          -- Differentiated anti-tumor activity observed particularly in 
             treatment-refractory and metastatic HPV-positive SCCHN, which is 
             poorly served by EGFR inhibitors (n=11) 
 
                 -- 45% ORR (confirmed and unconfirmed); 27% confirmed so far 
                    with a DOR >5.3 months with multiple patients remaining on 
                    treatment 
 
                 -- 100% disease control 
 
                 -- The one patient who achieved a CR continues in complete 
                    remission, now at greater than 16 months ongoing 
 
                 -- Oz-V continues to be well-tolerated, consistent with 
                    previous reports 
   -- Phase 1 and Phase 2 trials of evalstotug, CAB-CTLA-4 (NCT05180799) across 
      multiple solid tumor types (median of 3 prior lines of treatment) 
 
          -- Observing compelling anti-tumor activity and a relatively low 
             incidence and severity of immune-mediated adverse events (imAEs) 
             in unresectable and/or metastatic melanoma patients treated with 5 
             mg/kg evalstotug in combination with PD-1 antibody (n= 7 
             evaluable) 
 
                 -- Encouraging ORR (71%) and DCR (100%) 
 
                 -- Well-tolerated with 25% grade 3 (no grade 4) imAEs in 
                    patients with exposures up to 18 weeks. 
 
          -- Across multiple tumor types, well-tolerated with 18% grade 3 (no 
             grade 4) imAEs (n = 17) with 5 mg/kg evalstotug in patients with 
             exposures up to 18 weeks. 
 
          -- Initiated partnering discussions Q1 2025 

Corporate Updates

   -- BioAtla is extending its runway beyond key clinical readouts in 1H 2026 
      by restructuring and realigning resources, which includes a workforce 
      reduction of over 30%. The Company estimates that it will incur 
      approximately $0.6 million of one-time cash payments related to the 
      workforce reduction, which will mostly be paid in the second quarter. 
 
   -- The Company intends to retain employees essential for supporting value 
      creation, advancing our priortized internal programs and partnering other 
      clinical assets. 

Presentations

   -- Abstract accepted for poster presentation titled "Exploratory Analysis 
      Showed Increased Overall Survival among Non-Small Cell Lung Cancer 
      (NSCLC) Patients with Mutated KRAS Compared with Wildtype KRAS in a Phase 
      2 Trial of Mecbotamab Vedotin (CAB-AXL-ADC)" at the European Lung Cancer 
      Congress (ELCC) 2025, posted on March 26th with presentation on March 
      28th. 
 
   -- Abstract accepted for poster presentation titled "Ozuriftamab Vedotin 
      (BA3021), a Conditionally Binding ROR2-ADC; Phase 2 experience in 
      Patients with Heavily Pretreated Squamous Cell Carcinoma of the Head and 
      Neck" at the Mayo Multidisciplinary Head and Neck Symposium 2025 on March 
      27th. 
 
   -- One abstract accepted for presentation at the American Society of 
      Clinical Oncology (ASCO) 2025, titled: 
 
          -- "Phase 2 Trial of Ozuriftamab Vedotin (BA3021), a Conditionally 
             Binding ROR2-ADC, in Patients with Heavily Pretreated Squamous 
             Cell Carcinoma of the Head and Neck" 

Fourth Quarter and Full Year 2024 Financial Results

Research and development (R&D) expenses were $11.6 million for the quarter ended December 31, 2024 compared to $22.7 million for the same quarter in 2023. The decrease of $11.1 million was due to lower clinical development expenses in 2024 due to lower overall enrollment across our clinical trials due to our program prioritization in 2023. We expect our R&D expenses to continue to decrease overall in the 1H of 2025 due to our recent restructuring and as we complete Phase 2 trials for several indications and focus our ongoing development on our prioritized programs.

General and administrative (G&A) expenses were $4.6 million for the quarter ended December 31, 2024 compared to $5.9 million for the same quarter in 2023. The $1.3 million decrease was primarily due to lower stock based compensation, personnel related costs and D&O insurance premiums.

Net loss for the quarter ended December 31, 2024 was $14.9 million compared to a net loss of $26.9 million for the same quarter in 2023.

Net cash used in operating activities for the full year ended December 31, 2024 was $72.0 million compared to net cash used in operating activities of $104.0 million for the same period in 2023. Cash used for the quarter ended December 31, 2024 was $7.5 million.

Cash and cash equivalents as of December 31, 2024 were $49.0 million, compared to $111.5 million as of December 31, 2023. We expect that cost reductions to be subsequently realized from our realignment of resources and focus on our two internal priority programs will provide the Company with sufficient runway to fund operations and achieve key clinical readouts in the first half of 2026.

Fourth Quarter and Full Year 2024 Conference Call and Webcast Details

The management of BioAtla, Inc. will host a conference call and webcast for the investment community today, March 27, 2025, at 4:30 pm Eastern Time. A live webcast may be accessed here:

https://viavid.webcasts.com/starthere.jsp?ei=1706186&tp_key=5cbe8a8a0e. The conference call can be accessed by dialing toll-free (800) 245-3047 or (203) 518-9765 (international). The passcode for the conference call is BIOATLA.

A replay of the webcast and slides with topline interim clinical data referenced on the call will be available through "Events & Presentations" in the Investors section of the company's website after the conclusion of the presentation and will be archived on the BioAtla website for one year.

About CAB-EpCAM x CAB-CD3 Bispecific T-cell Engager Antibody

BioAtla is developing BA3182 as a potential anticancer therapy for patients with advanced adenocarcinoma. BA3182 is a (CAB) EpCAM x (CAB) CD3 bispecific T cell engager antibody that contains two binding sites for EpCAM and two binding sites for CD3 . The binding sites for EpCAM and CD3 have been designed to bind their respective targets specifically and reversibly under the conditions found in the TME and to have reduced binding outside of the TME. The CAB selective binding to both the CAB EpCAM and CAB CD3 arms are required to activate the T cell engagement against the tumor, thus enabling the combined selectivity of each CAB binding arm in the bispecific antibody. BioAtla continues to advance the ongoing Phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of BA3182 in advanced adenocarcinoma patients.

About Mecbotamab Vedotin

Mecbotamab vedotin (Mec-V), CAB-AXL-ADC, is a conditionally and reversibly active antibody drug conjugate targeting the receptor tyrosine kinase AXL. This Phase 2 stage clinical asset is targeting multiple solid tumor indications, including mKRAS NSCLC patients who have previously progressed on PD-1/L1, epidermal growth factor receptor or ALK inhibitor therapies.

About Ozuriftamab Vedotin

Ozuriftamab vedotin (Oz-V), CAB-ROR2-ADC, is a conditionally and reversibly active antibody drug conjugate directed against ROR2, a transmembrane receptor tyrosine kinase that is present across many different solid tumors including head and neck, lung, triple-negative breast cancer and melanoma. Overexpression of ROR2, a noncanonical wnt5A signaling receptor, forms a cancer axis that is associated with poor prognosis and resistance to chemo- and immunotherapies. This Phase 2 stage clinical asset is targeting multiple solid tumor indications, including initially the treatment of SCCHN HPV+ and HPV- patients who have previously progressed on PD-1/L1 therapies with or without platinum chemotherapy. The FDA granted Fast Track Designation to ozuriftamab vedotin for the treatment of patients with recurrent or metastatic SCCHN.

About Evalstotug

Evalstotug, is a CAB anti-CTLA-4 antibody that is being developed as an immuno-oncology agent with the goal of delivering efficacy at least comparable to the approved anti-CTLA-4 antibodies, but with lower toxicities due to the CAB's tumor microenvironment $(TME)$-restricted activity. This is anticipated to enable safer anti-CTLA-4 antibody combination therapies, such as with anti-PD-1 antibody checkpoint inhibitors, and potentially broaden the patient population tolerant to combination therapy and deliver greater efficacy. Like our other CAB candidates, this Phase 2 clinical asset is designed to be conditionally and reversibly active in the TME. Evalstotug is being developed as a potential therapeutic for multiple solid tumor indications that are known to be responsive to CTLA-4 treatment in combination with a PD-1 blocking agent.

About BioAtla$(R)$ , Inc.

BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB platform technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla's first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. The Company also has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. To learn more about BioAtla, Inc. visit www.bioatla.com.

Forward-looking Statements

Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "expect," "believe," "will," "may," "should," "estimate," "project," "outlook," "forecast" or other similar words. Examples of forward-looking statements include, among others, statements we make regarding BioAtla's business plans and prospects and whether our clinical trials will support registration; achievement of milestones; results, progress and timing of our research and development programs and clinical trials; expectations with respect to enrollment and dosing in our clinical trials, plans and expectations regarding future data updates, clinical trials, regulatory meetings and regulatory submissions; the timing of and the ability to establish collaborations or other strategic partnerships for selected assets; the potential regulatory approval path for our product candidates; expectations about the sufficiency of our cash and cash equivalents to fund operations and expectations regarding R&D expenses and cash burn, and expected cost reductions from our workforce reduction. Forward-looking statements are based on BioAtla's current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: factors that raise substantial doubt about our ability to continue as a going concern and that we will need additional funding to continue development of our CAB technology platform and our CAB product candidates; potential delays in clinical and preclinical trials; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, or regulatory approval dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; whether regulatory authorities will be satisfied with the design of and results from the clinical studies or take favorable regulatory actions based on results from the clinical studies; our dependence on the success of our CAB technology platform; our ability to enroll patients in our ongoing and future clinical trials; the successful selection and prioritization of assets to focus development on selected product candidates and indications; our ability to form collaborations and partnerships with third parties and the success of such collaborations and partnerships; our reliance on third parties for the manufacture and supply of our product candidates for clinical trials; our reliance on third parties to conduct our clinical trials and some aspects of our research and preclinical testing; potential adverse impacts due to geopolitical or macroeconomic events outside of our control, including health epidemics or pandemics; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on

Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 27, 2025 and our other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and BioAtla undertakes no duty to update such information except as required under applicable laws.

Internal Contact:

Richard Waldron

Chief Financial Officer

BioAtla, Inc.

rwaldron@bioatla.com

858.356.8945

External Contact:

Bruce Mackle

LifeSci Advisors, LLC

bmackle@lifesciadvisors.com

 
                          BioAtla, Inc. 
       Unaudited Statements of Operations and Comprehensive 
                               Loss 
                          (in thousands) 
 
                      Three Months Ended     Twelve Months Ended 
                         December 31,            December 31, 
                     --------------------  ----------------------- 
                       2024       2023       2024        2023 
                      -------               ------- 
Collaboration and 
 other revenue       $     --   $     --   $ 11,000   $      -- 
Operating expenses: 
    Research and 
     development 
     expense           11,650     22,674     63,095     103,731 
    General and 
     administrative 
     expense            4,594      5,862     21,848      25,956 
Total operating 
 expenses              16,244     28,536     84,943     129,687 
                      -------    -------    -------    -------- 
Loss from 
 operations           (16,244)   (28,536)   (73,943)   (129,687) 
Other income: 
    Interest income       554      1,638      3,369       6,312 
    Gain (loss) on 
     warrant 
     liability            807         --        807          -- 
    Other income 
     (expense)             (1)       (27)        (9)        (87) 
Total other income      1,360      1,611      4,167       6,225 
                      -------    -------    -------    -------- 
Net loss and 
 comprehensive 
 loss                $(14,884)  $(26,925)  $(69,776)  $(123,462) 
                      =======    =======    =======    ======== 
 
 
 
                              BioAtla, Inc. 
                            Balance Sheet Data 
                              (in thousands) 
 
                                           December 31,     December 31, 
 
                                               2024             2023 
                                          --------------   -------------- 
                                           (unaudited) 
Cash and cash equivalents                  $      49,046    $     111,471 
Total assets                                      52,422          119,658 
Total current liabilities                         14,540           28,344 
Total liabilities                                 38,157           48,986 
Total stockholders' equity                        14,265           70,672 
Total liabilities and stockholders' 
 equity                                           52,422          119,658 
 

(END) Dow Jones Newswires

March 27, 2025 16:05 ET (20:05 GMT)